A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world.
Amgen has created a number of websites to better serve you with specific questions.
We recognize that this may be a challenging and stressful time, especially if you are a patient managing a serious illness. As the COVID-19 pandemic continues to evolve, we are committed to doing everything we can to deliver for patients, to keep our staff and their families safe, and to help the communities where we live and work reduce the number of people exposed to the virus. Medical professionals around the world are working tirelessly on the front lines to achieve this and we would like to express our deep gratitude to them. We will continue to keep you informed and are committed to continuing to deliver to you our medicines.
For general information in Europe related to the pandemic, please see COVID-19 guidance from the World Health Organization or the European Center for Disease Control and Education
For further information on how Amgen is responding to the pandemic, please visit Amgen’s COVID-19 Information Center. Local contact information by country can be found here (Amgen’s global website).
Patients with cancer are disproportionately affected by COVID-19 and this has affected presentation, referral, diagnosis and treatment. Delays across each of these stages are predicted to increase the number of deaths from cancer that could otherwise be avoided. The video below (using UK data) presents this evidence and makes an urgent ‘call to action’ on behalf of patients, for us to work together to increase capacity in cancer care.